Inhibits antioxidant enzymes, manganese superoxide dismutase, glutathione peroxidase 2, and thioredoxin reductase 2 in prostate cancer cell lines, sensitizing them to ionizing radiation. Improves radiotherapy for aggressive tumors, including advanced prostate cancer. Here, TXNRD2 is linked to prostate carcinoma.